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Abbreviations 
5-aza-dC       5-Aza-2`- deoxycytidine 
ACTB          β-actin 
ad             adenocarcinoma 
B2M           β2-microglobulin 
BSA           Sodium bisulfite sequencing analysis 
COBRA        Combined Bisulfite Restriction Analysis 
DMSO         dimethylsulfoxide 
DW            distilled water 
FBS           fetal bovine serum 
FCS           fetal calf serum 
GFP           green fluorescent protein 
GL2           Photinus pyralis luciferase 
HDAC         histone deacetylase 
la             large cell carcinoma 
MAPK         mitogen-activated protein kinase  
MMP          matrix metalloproteinase 
mt            mutant-type 
NF-κB     nuclear factor κB 
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NSCLC        non-small cell lung carcinoma  
PBS           phosphate buffered saline 
PRDM2    PR domain containing 2 with ZNF domain 
qRT-PCR     quantitative real-time RT-PCR 
RAGE        receptor for advanced glycation endproducts 
RIZ      retinoblastoma protein-binding zinc finger protein 
RT-RCR      reverse transcription-polymerase chain reaction 
S100A4       soluble in 100% ammonium sulphate solution-family member A4 
SCLC         small cell lung carcinoma 
SDS-PAGE    sodiumdodecylsulphate polyacrylamide gel electrophoresis  
siRNA         small interfering RNA 
sm            small cell lung carcinoma 
sq            squamous cell carcinoma 
TSA           trichostatin A 
wt            wide-type 
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1. Abstract 
 
S100A4, a small calcium-binding protein belonging to the S100 protein family, is 
overexpressed in a variety of tumors, and seems to associate with metastasis. 
Previous studies on pancreatic cancer demonstrated the important roles played by 
S100A4 in cell proliferation and motility. In the present study, biological roles of 
S100A4 in lung carcinogenesis were analyzed. S100A4 was frequently 
overexpressed in lung cancer cells, irrespective of histological subtypes. 
Hypomethylation at the CpG sites in intron 1 is reported as the main cause of 
abnormal upregulation. Specific knockdown of S100A4 effectively suppressed cell 
proliferation only in lung cancer cells with S100A4-overexpression, and forced 
expression of S100A4 accelerated cell motility only in S100A4 low-expressing lung 
cancer cells. PRDM2 and VASH1 were previously identified by microarray analyses 
as upregulated genes after specific knockdown of S100A4 in pancreatic cancer. 
These genes were also analyzed and found that PRDM2 was significantly 
upregulated after S100A4-knockdown in one of the two analyzed 
S100A4-overexpressing lung cancer cells. Present results suggest that S100A4 plays 
an important role in lung carcinogenesis by means of cell proliferation and motility, 
probably by similar mechanisms as were observed in pancreatic cancer.  
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2. Background 
 
Primary lung cancer is one of the most frequently occurring malignancies and is 
the leading cause of cancer-related death in men and the second leading cause in 
women in Japan1). Lung cancer is divided into two major types, non-small cell lung 
carcinoma (NSCLC) and small cell lung carcinoma (SCLC); former accounts for 
approximately 85% of all lung cancer cases and typical histopathological types are 
adenocarcinoma, squamous cell carcinoma, and large cell carcinoma2). Although 
5-year survival rate significantly improved over the last 30 years, overall survival rate 
is still 17% in the USA3), 14.9% in Japan4). The early signs and symptoms of lung 
cancer are non-specific; as a consequence, the great majority of patients are 
diagnosed at advanced stages, making difficulties in successful treatment and 
worsened prognoses5). Although various refinements of the conventional therapies 
have been attempted to lung cancer such as surgery, radiation therapy, 
chemotherapy, the improvement in the survival rate is still limited4). Therefore, there is 
an urgent need for improvement of clinical management of patients with lung cancer; 
novel approaches to both diagnosis and treatment are necessary. In this point of view, 
identification of new key molecules that play roles in proliferation, migration and 
invasiveness are indispensable.    
A variety of genes including p536), K-ras7), cyclin D18) and p279) were reported to 
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associate with lung carcinogenesis. However, above-mentioned genes cannot explain 
the full story of lung carcinogenesis. One molecule potentially of interest in lung 
cancer is S100A4. This molecule belongs to the S100 family, a calcium binding 
protein family characterized by the EF-hand motif and is emerging as a multifunctional 
player in cell proliferation, differentiation, metabolism, adhesion, motility, 
angiogenesis and signal transduction10). To date, 22 members have been assigned to 
the family and most of them are mapped to human chromosome 1q2111), a region 
which is frequently rearranged in human cancers12). Some members of S100 family 
other than S100A4, such as S100A2, S100A613), S100A714), S100A8, S100A915), 
S100A1116), S100P, and S100B, have been postulated to play roles in the 
progression of a number of human cancers17). 
S100A4 protein has been reported in its importance in human carcinogeneses in 
various types of cancers such as cancers of urinary bladder18), breast19), colorectal20), 
gastric21), pancreatic22) and prostate cancer23), and also expression of S100A4 in lung 
cancer has been reported; 60% (81 of 135) in NSCLC27), 67.2% (137 of 204) in 
squamous cell carcinomas28). Furthermore, upregulation of S100A4 significantly 
associated with poor prognosis in adenocarcinoma29). Frequent upregulation of 
S100A4 was previously reported in pancreatic cancer24), and siRNA-mediated 
knockdown of S100A4 caused apoptosis and inhibition of cell motility only in cells with 
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upregulated S100A424). On the other hand, forced expression of S100A4 accelerated 
cell motility only in cells with downregulated S100A425). It is of great interest to 
analyze whether or not S100A4 has similar biological roles in lung cancer, especially 
those could explain its metastasis promoting ability.  
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3. Aim 
 
To elucidate the potential role of S100A4 in lung carcinogenesis, I performed 
comprehensive analyses of the expression and biological roles of S100A4 in 
human lung cancer. siRNA-mediated downregulation and expression 
vector-mediated upregulation experiments were performed to analyze cell growth 
and migration. I also analyzed possible downstream genes of S100A4 after 
downregulation in lung cancer cell lines. 
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4. Materials and Methods 
 
4.1.  Lung cancer cell lines and cell culture  
In this study, a total of 14 human lung cancer cell lines were used: seven 
adenocarcinomas (A549, PC9, LK87, 11-18, HLC-1, LCSC#2, HT-1), three squamous 
cell carcinomas (Sq-1, Sq-19, HS-24), two large cell carcinomas (Lu65, Lu99c), and 
two small cell carcinomas (SBC-3, LK79). These cells were already used in previous 
studies4,29). An immortalized normal human lung epithelial cell, BEAS-2B was also 
used as the control. These cells were maintained as described4,29). Briefly, A549, PC9, 
LK87, 11-18, LCSC#2, HT-1, Sq-1, Sq-19, HS-24, LK79 were maintained in 
RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS); SBC-3 and 
BEAS-2B were maintained in E-MEM medium supplemented with 10% fetal calf 
serum (FCS); HLC-1 was maintained in HamF12 medium supplemented with 
10%FCS. All the cells were cultured in a humidified incubator at the condition of 37oC 
and 5%CO2 
 
4.2.  Western blotting 
Harvested cells were subjected to extraction their proteins and the concentrations 
of proteins were measured using the DC protein assay kit (Bio-Rad, Hercules, CA). 
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Sodiumdodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting was used to analyze protein expression levels. An aliquot of each 40 
µg protein was electrophoresed in a 5-20% polyacrylamide gradient gel (SuperSep 
Ace, Wako, Japan) and subjected to Western blotting as described previously32).The 
antibodies used were rabbit anti-S100A4 polyclonal antibody (DakoCytomation, 
Denmark), mouse anti-Myc-Tag monoclonal antibody (MBL, Japan), mouse anti-β 
actin monoclonal antibody (Sigma, St Louis, MO), and horseradish peroxidase 
conjugated anti-mouse or anti-rabbit immunoglobulin antibodies (Amersham 
Biosciences Corp., Piscataway, NJ) and conditions followed by the manufacturer’s 
recommendations. Signals were visualized by reaction with ECL Detection Reagent 
(Amersham Biosiences Corp.) and digitally processed using LAS 4000 Plus with 
ImageQuant TL software (GE Healthcare, Piscataway, NJ). 
 
4.3.  RNA  extraction   
Total RNAs were isolated using RNeasy Midi Kit (QIAGEN, Valencia, CA). Then 
RNAs were run on a 1% agarose gel and concentrations were spectrometrically 
measured at 260 and 280 nm using a NanoDrop ND-1000 Spectrophotometer 
(Thermo Fisher Scientific Inc., Pittsburgh, PA).  
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4.4.  Reverse transcription-polymerase chain reaction (RT-PCR) 
An aliquot of each 2µg extracted RNA was used for cDNA synthesis by High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). 
Quantitative RT-PCR (qRT-PCR) using the ABI PRISM 7000 (Applied Biosystems) 
was performed as described31). For normalization of expression of the analyzed genes, 
β2-microglobulin (B2M)32) was monitored as the representative housekeeping gene 
and the ratio of gene of interest and B2M was calculated. Control templates were 
prepared by PCR amplification of the mixture of several cDNA libraries consisting of 
fetal brain and liver, adult kidney, pancreas, lung, liver, ovary, fibroblast and colon33). 
Primers and probes were previously designed24,25) as shown in the Table 1. 
 
4.5.  DNA extraction 
Genomic DNAs from cultured cells were extracted by DNeasy Blood&Tissue Kits 
(Qiagen) according to the manufacturer`s instructions, and their concentrations were 
also measured with a NanoDrop ND-1000 Spectrophotometer. All the processes were 
carried out according to the manufacturer`s instructions. 
 
4.6.  Sodium bisulfite sequencing analysis (BSA)  
Sodium bisulfite treatment for methylation analysis was performed by the method 
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described previously34) with some modification35). Cytosine residues in 
single-stranded DNA are converted into uracil residues and recognized as thymine in 
subsequent PCR amplification and sequencing. However, if cytosine residues are 
methylated at position 5 (5-methyl cytosine), mainly at the CpG sites, speed for above 
mentioned conversion is very slow and remain as cytosines. Thus, we can 
discriminate cytosine and methylated cytosine residues. An aliquot of 2µg of each 
genomic DNA was used for bisulfite treatment by Epitect Bisulfite Kit (Qiagen), and 
50ng bisulfite-modified DNA was amplified by PCR. Then, each amplified DNA was 
purified and methylation status was determined by checking nucleotide sequence as 
described previously36). 
 
4.7.  Combined Bisulfite Restriction Analysis (COBRA) 
    In the present study, intron 1 of S100A4 gene was determined because 
hypomethylation in this region was reported to associate with expression22). 
Combined Bisulfite Restriction Analysis (COBRA) was performed for this purpose and  
methods reported by Xiong et al.37) were applied.  Two HpyCH4IV sites are to be 
created after the bisulfite modification when cytosine residues at the first and second 
CpG sites in intron 1 were methylated. Bisulfite-treated DNAs were PCR-amplified at 
intron 1 of the S100A4 gene (position between +252 and +393 in Figure 2). Then the 
DNAs were purified and digested with HpyCH4IV and electrophoresed using 3% 
16 
 
agarose gels. 
 
4.8.  5-Aza-2`- deoxycytidine (5-Aza-dC) and trichostatin A (TSA) treatments 
   A total of 2x106 cells were seeded into 10cm dishes and were maintained for 72h 
while replacing the culture medium every 24h; these culture media contain 5-aza-dC 
(Sigma, St. Louis, MO) at 5 μM as the final concentration. Subsequently, at the time 
point of 72h, cells were treated with 5-aza-dC at the final concentration of 5 μM or 1 
μM TSA (Wako, Osaka, Japan) at the final concentration of 1μM for another 24 h. 
Another 2x106 cells were also plated in a 10cm dish with TSA treatment alone at the 
final concentration of 1 μM and cultured for 24h. All these cells were harvested at 
appropriate time point and RT-PCR analyses were done by the methods described 
previously35).  
 
4.9.  Short interference RNA transfection 
Oligonucleotides of short interference double-strand RNA targeting against 
S100A4 was used as described24), siRNA corresponding to nucleotides 215-233 
relative to the initiating codon (5’-GGACAGAUGAAGCUGCUUUdTdT-3’ and 
5’-AAAGCAGCUUCAUCUGUCCdTdT-3’) was used38); and siRNA against Photinus 
pyralis luciferase (GL2) was used as the control39), with 
5`-CGUACGCGGAAUACUUCGA-3` in the sense strand. These siRNAs were 
purchased from Integrated DNA Technologies MBL (Nagoya, Japan). A total of 2 x 105 
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cells were plated in 6-well plates and allowed to adhere for 24 hours and were 
transfected using the Lipofectamine RNAi MAX reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. 
 
4.10.  Cell proliferation assay 
A total of 1 x 104 cells were plated in 24-well plates 24h after transfection. Cells 
from three sets of wells were harvested and counted every 24h up to 120h using 
Countess Automated Cell Counter (Invitrogen) according to methods by the supplier. 
These cells were pelleted for further investigation of S100A4 expression. All 
experiments were performed in triplicate.  
 
4.11.  Cell Scratch assay 
Each 2 x 105 cells was seeded in a 6-well plate after the siRNA or plasmid 
transfection. Cells were grown for 24h to create a confluent monolayer. Then the 
bottom of each well was scraped with a 200μl-micropipet tip. This time point was set 
as time 0. Plates were washed twice with PBS to remove detached cells and 
incubated with the complete growth medium. Wounded empty spaces were measured 
and photographed over time until the empty spaces were closed. Each scratch assay 
was performed in triplicate.  
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4.12.  S100A4 expression vector cloning 
The entire coding region of S100A4 cDNA was PCR-amplified with a primer pair 
S100A4-Forward (5`-AGAAGATCTCCACCATGGCGTGCCCTCTGGAG-3`) and 
S100A4-Reverse (5`-TTACTCGAGTTTCTTCCTGGGCTGCTTAT-3`). Kozak 
consensus sequence was added to increase the translation efficiency, and Bgl II and 
Xho I restriction endonuclease sites for forward and reverse primers, respectively, 
were facilitated for directional cloning. The PCR product was digested with these 
enzymes, and then ligated into BamH I and Xho I double-digested pcDNA6/myc-His 
vector. The nucleotide sequence of cloned S100A4 construct was confirmed by direct 
sequencing (Applied Biosystems) and the cloned vector was named 
pcDNA6-S100A4. 
 
4.13.  Forced expression of S100A4 in lung cancer cell lines 
The previously cloned S100A4 expressing plasmid, pcDNA6-S100A4 was used. 
Transfection of the plasmid was performed using a total of 2 x 105 cells plated in 
6-well plates. Cells were allowed to adhere for 24 h and then the transfection was 
done using Lipofectamine 2000 reagent (Invitrogen) according to the supplier’s 
protocol. An empty plasmid pcDNA6/myc-His was also transfected as the control. To 
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assess transfection efficiency, green fluorescent protein (GFP) reporter plasmid 
pSUPER.retro.neo+GFP was co-transfected with either pcDNA6-S100A4 or 
pcDNA6/myc-His in 6-well culture dishes; the molar ratio was as follows; pcDNA6 
plasmid : reporter plasmid = 10 : 1. Briefly, 3×104 cells / well were seeded on BD 
BioCoat Fibronectin 4-well CultureSlides (BD Biosciences, Bedford, MA) 24h after the 
co-transfection. The fluorescent images were obtained 48h after transfection with a 
Zeiss LSM5 PASCAL confocal microscope system (Carl Zeiss Inc., Thornwood, NY) 
as described previously40). Cells with successful transfection were used for analyses 
of cell growth and motility after induction of S100A4. 
 
4.14.  Statistical analysis 
All experiments were performed in triplicate. A two-tailed Student’s t-test was used 
for statistical analyses of comparative data using Microsoft Excel software (Microsoft 
Corporation, Tokyo, Japan). All significance tests were two-sided, and values of 
p<0.05 were considered as significant. 
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5. Results  
 
5.1. Expression analysis of S100A4 in lung cancer cell lines 
Expression of S100A4 in primary lung resected tumor tissue was investigated in 
several studies.27,28,29) S100A4 expression was first examined in 14 lung cancer cell 
lines covering four major histological types (adenocarcinoma, squamous cell 
carcinoma, large cell carcinoma, and small cell lung carcinoma) and BEAS-2B, a cell 
line established from normal bronchial epithelium as the control. Representative 
results were shown in Figure 1A by Western blotting. Distinct expression levels of 
S100A4 were observed among cell lines, but high level of S100A4 expression was 
frequent when compared with that of BEAS-2B; six of seven adenocarcinomas, two of 
three squamous cell carcinomas, one of two large cell carcinomas, and one of two 
small cell carcinomas. Two adenocarcinomas (11–18 and HLC-1) and two SCLCs 
(SBC-3 and LK79) were selected as representing the low- and high-level expressing 
cells, respectively, and were subjected to further characterization. Results of RT-PCR 
were also shown in Figure 1B and C; the mRNA expression levels were in good 
agreement with the protein expression levels. 
 
5.2. DNA methylation analysis by BSA and COBRA 
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Rosty et al.22) have reported that overexpression of S100A4 correlates with DNA 
hypomethylation of intron 1. To investigate the methylation status of S100A4, the 
sodium bisulfite sequencing analysis was performed at first. Results were showed in 
Fig. 2A. The important 4 CpG sites were demonstrated. Among these sites, site 1 and 
site 2 harbored the sequence of ACGT which can be cut by the restriction enzyme 
using COBRA. 
Next, the DNA methylation analyses by COBRA in lung cancer cell lines were 
performed and  results were shown in Fig. 2B. As it was shown in Fig. 2A that CpG 
site 1 and 2 formed a sequencing of ACGT which could be digested by restriction 
enzyme HpyCH4IV following the bisulfite treatment, and  these two sites were 
related with the methylation in certain pancreatic cell lines(unpublished data), it was 
possible to check the methylation status of these two sites by COBRA.  The forward 
and reverse primers were designed  for this bisulfite-treated sequencing (see Fig. 2A 
and Table 1) that covered the two sites, after PCR amplification, the product was 
digested by HpyCH4IV. If both sites were methylated, two ACGT sequences would be 
cut into three parts as 26bp、16bp、100bp; If both sites were unmethylated, it would be 
no digestion of the amplified product as cytosine changed into thymine; If only one site 
was methylated (partial methylation), 42bp+100bp or 26bp+116bp would be expected.  
Based on this analysis, S100A4 low-expressing cell line 11-18, Lu99c, SBC-3 
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were methylated, S100A4 moderate-expressing cell line Sq-1 was partially 
methylated, and S100A4 over-expressing cell line A549, LK87, HT-1, Sq-19, Lu65, 
LK79, HLC-1 were unmethylated. However, there was an except that low-expressing 
cell line HS-24 was hypomethylated.  
 
5.3. Restoration of S100A4 expression after 5-aza-dC and/or TSA treatment 
To determine whether epigenetic mechanism contributes to suppression of the 
S100A4 transcription, lung cancer cell lines were analyzed by treatments with a 
demethylation agent, 5-aza-dC, and/or a histone deacetylase (HDAC) inhibitor, TSA. 
Analyzed cells were HS-24, Sq-19, 11-18, and  results were shown in Fig. 2C. 
S100A4 low-expressing cell line 11-18 had an increased expression with a decreased 
methylation by 5-aza-dC treatment. However, HS-24 was significantly upregulated by 
TSA treatment, and no alteration of methylation status was observed. In addition, no 
change was observed in S100A4 over-expressing cell line Sq-19.   
 
5.4. Effects of siRNA-mediated knockdown against S100A4 in lung cancer 
cells 
   To address the question whether S100A4 could serve as a therapeutic target for 
lung cancer, I employed siRNA-mediated knockdown in an attempt to deplete the 
expression of S100A4 in lung cancer cell lines. 19-mer double-stranded 
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oligoribonucleotides targeting against S100A4 and luciferase (GL2) were prepared, 
and the siRNA transfections were performed at 0nM, 2nM, 20nM, and 200nM with the 
Lipofectamine RNAi MAX reagent. After 72 hours, the cells were harvested and total 
RNA and cell lysates were prepared for determination of S100A4 expression levels; 
quantitative real-time RT-PCR (qRT-PCR) analysis and western blot analysis were 
performed. As shown in Fig. 3, effective suppression of S100A4 expression was 
observed by both qRT-RCR and Western blotting analyses in a dose-dependent 
manner. No morphological differences were observed after knockdown of S100A4 in 
all the analyzed cells (data not shown).  
 
5.5. Effects of siRNA-mediated knockdown against S100A4 on cell growth  
As one of the phenotypic analyses after downregulation of S100A4, the cell growth 
was first investigated with cell proliferation assay by counting cell number directly, and 
results were shown in Fig. 4. Suppression of proliferation was observed only in 
S100A4-overexpressing cell lines, HLC-1 and LK79 (Fig. 4A). In contrast, no growth 
suppression was observed in 11-18 and SBC-3, cell lines without 
S100A4-overexpression (Fig. 4B). Because no such differences were observed in 
knockdown of GL2, it was highly presumable that knockdown of S100A4 specifically 
suppressed the growth in S100A4-overexpressing cell lines.  
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5.6. Effects of siRNA-mediated knockdown against S100A4 on cell motility 
In order to investigate whether S100A4 knockdown affects cell motility, scratch 
assay was performed. The siRNA transfection was done at 200nM/L to obtain 
complete suppression of S100A4 expression. As shown in Fig. 5A, silencing of 
S100A4 reduced speed to fill wounded empty space in HLC-1 and LK79; whereas no 
such differences were evident in 11-18 and SBC-3 (Fig. 5B). However, speed to fill 
wounded empty space seemed to show parallel association with cell growth, it is likely 
that speed to fill wounded space mainly depended on cell growth after downregulation 
of S100A4 in lung cancer cells. (Fig. 5C). 
 
5.7. Effects of S100A4 overexpression in lung cancer cells 
Sekine et al. previously observed that forced expression of S100A4 induced cell 
motility without stimulation of cell growth in human pancreatic cancer cell lines25). In 
this study, cell proliferation and motility in lung cancer cell lines were analyzed after 
introduction of S100A4-expression vector as was previously performed in pancreatic 
cancer. In order to monitor the efficiency of transfection, we performed co-transfection 
of pSUPER.retro.neo+GFP with pcDNA6-S100A4. Forced expression was successful 
in used cell lines 11-18, HLC-1, SBC-3 and LK79 as shown in Fig. 6A. Results of 
RT-PCR and Western blotting also supported successful transfection (Fig. 6B, C). It is 
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notable that no significant morphological differences were evident after the 
introduction of S100A4 (data not shown). 
 
5.8. Effects of forced expression of S100A4 in cell growth  
Because specific knockdown of S100A4 induced suppression of cell proliferation 
as shown in Fig. 4, I performed proliferation assay as described above to address the 
question of whether forced expression of S100A4 accelerates cell growth. Results 
were shown in Fig. 7; no proliferative accelerations were observed in lung cancer cells 
of both S100A4-low expression (Fig. 7A) and S100A4-overexpression (Fig. 7B).  
 
5.9. Effects of forced expression of S100A4 on cell motility  
To elucidate the role of forced expression of S100A4 on cell migration, scratch 
assay after induction of S100A4 was performed. It is notable that acceleration of cell 
motility were evident in S100A4-low expressing lung cancer cells after forced S100A4 
expression (see Fig.8A), but not in S100A4-overexpressing cells (Fig. 8B). Statistical 
analysis indicated that the acceleration of cell motility was significant (P<0.01 for 
11-18 and P<0.001 for SBC-3).  
 
5.10. Possible molecular regulators were induced to express after knockdown 
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of S100A4 
To investigate the possible roles played by S100A4 in lung carcinogeneses, 
expression of the PRDM2/RIZ and VASH1/Vasohibin genes were also analyzed 
because these genes were upregulated after siRNA-mediated knockdown of S100A4 
in the previous studies on pancreatic cancer24). After 72h of S100A4-knockdown in 
HLC-1, and LK79 by qRT-PCR, upregulation of PRDM2 was observed only in HLC-1 
(Fig. 9A). In contrast, no expression change was observed in LK79. No significant 
expression change of VASH1 was observed (Fig. 9B).   
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6. Discussion 
Despite recent improvements in the diagnosis and treatment have greatly 
improved the five-year survive rate, lung cancer is still the one of the most common 
and life-threatening cancer1). Its aggressive invasion and frequent metastases to other 
organs raise the difficulty of early diagnosis, and discovering effective biomarkers, 
novel therapeutic targets seem to be useful to solve the problems. Recently, 
molecularly targeted therapies, such as gefitinib41), erlotinib42) and bevacizzumab43), 
have recently been developed for the treatment of adenocarcinoma. In these respects, 
the understanding of the molecular mechanisms on the process of lung cancer 
carcinogenesis is emerging. 
S100A4 (also named MTS1, P9KA, PEL98, and CAPL), a member of the 
Ca2+-dependent S100 protein family, is located on human chromosome 1(1q21), a 
region that is frequently rearranged in different cancers12). In many cases, 
S100A4-upregulation has been correlated with poor prognosis in cancers of 
prostate23), lungs27), esophagus44), colorectum45), stomach46) and breast47), and the 
development of metastasis and invasion48,49). In the previous study on pancreatic 
cancer, siRNA-mediated knockdown of S100A4 promoted cell death mainly mediated 
by induction of apoptosis only in cancer cells with high expression of S100A4, and 
forced expression of S100A4 induced accelerated cell motility only in pancreatic 
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cancer cells with low expression24,25).  
To analyze whether or not the expression of S100A4 in pancreas and lungs have 
similar influence on cancer cells, expression statuses of the S100A4 in human lung 
cancer cell lines were first analyzed; S100A4 was frequently upregulated in lung 
cancer cell lines. Then, the RNA interference (RNAi) method was used to evaluate the 
importance of the S100A4 protein in order to elucidate the possibilities for utilization of 
S100A4 in the treatment of human lung cancer. Further, forced expression methods 
were also used to examine the effects of S100A4 on cell proliferation and migration of 
lung cancer cells in vitro. Finally, possible related downstream genes of S100A4 were 
analyzed that were previously picked-up in pancreatic cancer24); PRDM2 was a 
candidate for S100A4-associated carcinogenesis.  
Recently, overexpression of S100A4 in various tumors has been reported 
including lung cancer50). In the present study, S100A4 was also found frequently 
upregulated in lung cancer cell lines. The major cause of overexpression of the 
S100A4 was reported to be hypomethylation in intron 122). The epigenetic alterations, 
mainly DNA methylation and histone modification, play important roles in 
carcinogenesis. Aberrant DNA methylation causes inactivation of tumor suppressor 
genes and/or activation of oncogenes, similar to genetic alterations51,52). The case 
also holds true of S100A4 gene. S100A4 hypomethylation has been associated with 
29 
 
its overexpression in pancreatic22), gastric52), prostate53), colorectal54), skin squamous 
cell carcinoma (SCC)55), endometrial carcinoma56), and lymphoma carcinoma cell 
lines57). Conversely, hypermethylation has been associated with transcriptional 
repression of S100A422). In the present study, lung cancer cell lines including four 
major histological types were used to study their DNA methylation status and found 
that the methylation status associated with mRNA and protein expression levels with 
an exception, HS-24. This cell line was categorized in S100A4 low-expression. 
Methylation status revealed that this cell line was partial methylated. 5-aza-dC did not 
change expression but TSA did upregulated S100A4 level in this cell line. These 
results indicate that methylation status mainly regulates S100A4, and histone 
acetylation is also playing a role in some cases. 
Tumor growth and metastasis depend on the increasing of cell proliferation, 
migration, invasion, and angiogenesis. S100A4 is involved in these processes via 
intracellular and extracellular protein interactions. Through protein interactions, 
S100A4 influences function of distinct intracellular targets including liprin-β158), 
myosin II-A59), tropomyosin60), and TP5361). These interactions may upregulate cell 
motility and modulate the function of TP5361). In addition to intracellular functions, 
there is also accumulating evidence that S100 proteins have extracellular functions to 
promote cell differentiation, proliferation, survival, motility, invasion, and 
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angiogenesis62-66). S100A4 has influence upon signal transduction cascades including 
mitogen-activated protein kinase (MAPK) phosphorylation67), receptor for advanced 
glycation endproducts (RAGE) signaling68), and NF-κB activation69). However, the 
precise molecular mechanisms of S100A4 remain complicated and unclear.  
siRNA-mediated knockdown of S100A4 decreased cell proliferation in pancreatic 
cancer24), osteosarcoma70), breast cancer71). In this study, the results on lung cancer 
showed a good agreement with previous reports; suppression of S100A4 suppressed 
cell proliferation in S100A4 overexpressing lung cancer cell lines. However, the 
morphology of apoptosis was not observed in S100A4 overexpressing lung cancer 
cell lines as previous study in S100A4 high-expressed pancreatic cancer cell lines. 
The explanation could be that knockdown of S100A4 slow down the cell cycle, in the 
checkpoint, S100A4 overexpressing lung cancer cell line HLC-1 and LK79 succeed in 
DNA repair, and escape from cell death; S100A4 overexpressing pancreatic cancer 
cell line could not finish the repair, and induce the apoptosis. Further study of cell 
cycle with FACS analysis could be used to confirm whether apoptosis happens. On 
the other hand, forced expression of S100A4 did not accelerate cell proliferation in 
lung cancer cells, even those without upregulation of S100A4 (11-18, SBC-3). This is 
basically the same results as were observed in the previous study of pancreatic 
cancer cells without upregulation of S100A4 (PCI-43, PCI-35). I speculated that 
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cancer cells with upregulation of S100A4 may depend on S100A4 function for cell 
proliferation, whereas those without upregulation of S100A4 may depend on some 
molecule(s) other than S100A4 for their cell proliferation. However, this is only a 
speculation and further studies are necessary.  
One of the possible explanations is a genetic and functional relationship between 
S100A4 and TP5312),61). The tumor suppressor protein TP53 is a transcription factor 
that maintains and regulates several cellular processes, and mutations in TP53 are 
observed in more than 50% of human cancers12). S100A4 binds to the extreme end of 
the C-terminal regulatory domain of TP53 in vitro and inhibit phosphorylation of the 
C-terminal domain of TP5361). S100A4 was reported to regulate negatively to cellular 
TP53 levels in human breast cancer19) and lung cancer72). Orre et al. reported that 
knockdown of S100A4 in two TP53 wild-type cell lines (A549 and HeLa) resulted in 
TP53-dependdent cell cycle arrest, but not apoptosis73). In this study, only SBC-3 has 
reported to harbor TP53 mutation74). Introduction of S100A4 in this S100A4 
low-expressing cell line did not affect cell growth. In the former study of pancreatic 
cancer cells, introduction of S100A4 in the S100A4 low-expressing and TP53wt cell 
line PCI-3575) did not alter cell proliferation as well; knockdown of S100A4 in S100A4 
over-expressing cell line MIAPaCa-2 and AsPC-1 which harbor mutation of TP53 
(R248W75) and Homozygous deletion (HD) in exon 575), respectively) induced 
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apoptosis24). There is a possibility that knockdown of S100A4 leads to 
TP53-independent cell cycle arrest. S100A4 could abolish the tumor suppressor 
function of TP53 by controlling TP53 nuclear translocation73). However, Berge et al. 
reported that up- or down-regulation of S100A4 exerted no effect on TP53 protein 
expression and did not influence the stabilization of TP5376). TP53-S100A4 interaction 
needs further investigation. 
Invasion and metastasis are leading causes of treatment failure in cancer patients 
and are significant predictors of poor prognosis. Increased motility is the first step in 
invasion and metastasis. I therefore investigated the effect of S100A4 on the motility 
in lung cancer cells and observed that S100A4 increased cell migration. This process 
depends on the rearrangement of cytoskeleton proteins such as actin, tropomyosin or 
myosin. S100A4 promotes cell migration via intracellular interaction by binding to 
non-muscle myosin II-A59), tropomyosin60) and actin77), in a Ca2+-dependent manner, 
and also by initiating cytoskeletal reorganization and/or by mediating MMP expression 
and release78). 
PRDM2 and VASH1 were identified as S100A4-suppression related genes in 
pancreatic cancer cell lines24). In this study, knockdown of S100A4 upregulated the 
expression of PRDM2. PRDM2, PR domain containing 2 with ZNF domain, also 
named retinoblastoma protein-binding zinc finger protein (RIZ), was isolated as a 
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candidate tumor suppressor gene by a functional screening for RB-binding proteins79), 
and aberrations of this gene were observed in a number of tumors such as pancreas, 
stomach, and colon80,81). The PRDM2/RIZ gene normally produces two protein 
products termed RIZ1 and RIZ2, of different size, with and without the PR domain. It 
has been reported that introduction of RIZ1 in hepatoma82) and breast cancer cells83) 
caused cell cycle arrest and programmed cell death. In the present study and the 
former study in pancreatic cancer cell lines, it is suggested that knockdown of S100A4 
induce apoptosis. Thus, upregulated expression of PRDM2 by downregulation of 
S100A4 may assist with S100A4 in cell cycle regulation. Furthermore, methylation 
mediated suppression of this gene in cancers of the breast and lung as well as 
neuroblastoma was reported84). It is anticipated that suppression of PRDM2 
expression is one of the downstream events of S100A4 upregulation in lung 
adenocarcinoma. Only two cell lines (HLC-1 and LK79) were investigated after 
knockdown of S100A4, further confirmation of the relationships between S100A4 and 
PRDM2 are necessary for elucidation of function of the S100A4 and PRDM2 in 
human carcinogenesis. 
Findings of S100A4 overexpression in lung cancer provide several potential 
clinical applications. However, expression of S100A4 was only investigated using 
cancer cells. Further investigations using normal and cancerous lung tissues are 
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necessary. Since high level of  S100A4 was reported in pancreatic cancer 
patients, there is a possibility that monitoring the S100A4 in blood/ biological 
fluids may potentially be a useful biomarker for clinical management of patients with 
lung cancer. Finally, S100A4 seems to be one of the mediators of lung cancer 
progression, it can be considered as a potential therapeutic target. Metastasis is the 
major cause of cancer deaths. Based on in vitro studies, downregulation of the 
expression of S100A4 may inhibit the metastatic ability of cancer cells85). Further 
studies on S100A4 will prove the possibility of molecular target therapy of S100A4. 
RNA interference method is considered to be an effective method for cancer 
therapy in vivo in the future85). An efficient delivery system of siRNA into solid tumors 
has been developed86). It is possible that RNAi-mediated suppression of S100A4 can 
be utilized as a specific molecular target therapy. Although further investigations are 
necessary, there is a hope that utilization of S100A4 as a prognostic marker and a 
therapeutic target.  
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7. Conclusion 
In this study, we investigated expression of S100A4 and biological responses in 
lung cancer cells after downregulation and upregulation of S100A4. We found that 
S100A4 is frequently overexpressed in lung cancer, irrespective of histopathological 
subtypes. Upregulation of S100A4 is mainly caused by hypomethylation in intron 1 as 
was reported in lung cancer. However, some other mechanisms may also play a role; 
lung cancer cell line HS-24 showed suppressed expression mainly caused by histone 
modification. Knockdown of S100A4 suppressed cell growth only in lung cancer cells 
with high level of S100A4, and forced upregulation of S100A4 promoted cell motility. 
Our present results may suggest that S100A4 can be an attractive biomarker for 
patients with lung cancer, and suppression of S100A4 will give benefits for patients 
with S100A4-upregulated lung cancer. Further investigations including 
characterization of genes downstream from S100A4 are necessary for obtaining 
valuable clues to improve the clinical management of patients with lung cancer. 
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Figure legends 
 
Figure 1. Expression analyses of S100A4 in lung cancer cell lines. Western blot 
analyses of S100A4 protein using anti-S100A4 rabbit polyclonal antibody.  
(A) Expression of β-actin (ACTB) was monitored as the internal control. The 
immortalized normal human lung epithelial cell BEAS-2B was used as the control. 
Ad, sq, la, and sm denote adenocarcinoma, squamous cell carcinoma, large cell 
carcinoma, and small cell lung carcinoma, respectively.  
(B, C) Expression of S100A4 in BEAS-2B and four selected lung cancer cell lines 
were determined by (B) RT-PCR, (C) qRT-PCR, respectively. Expression of the 
B2M gene was monitored as the internal control.  
 
Figure 2. DNA methylation and histone modification analyses.  
(A) Nucleotide sequences before (bottom) and after (top) bisulfite treatment are 
shown. CpG sites are indicated by bold characters and numbered. Solid lines indicate 
location of the primers (indicated by arrows) used in bisulfite sequencing analysis 
(BSA) and combined bisulfite restriction analysis (COBRA). The letter “T” above “C” 
indicates the modified cytosine residues after bisulfite treatment.  
(B) Results of COBRA in analyzed cell lines. HpyCH4IV sites after PCR using sodium 
bisulfite treated-DNAs are shown. Sizes indicate possible length of fragments after 
61 
 
digestion with HpyCH4IV. 142-bp region was amplified and then digested with 
HpyCH4IV and electrophoresed. 142-bp band is an indicator for unmethylation (U) 
and 100-bp band is an indicator for methylation (M). 116-bp band along with 
co-existence of 142-bp and 100-bp bands are indicators for partial methylation (P). 
(C) Restoration of S100A4 expression after 5-aza-dC and/or TSA treatment analyzed 
by RT-PCR and COBRA. mRNA expression of S100A4 was analyzed by RT-PCR. 
Expression of B2M was monitored as the internal control. Control, 5-aza-dC, TSA, 
5-aza-dC+TSA were indicated by C, A, T, AT, respectively.  
 
Figure 3. siRNA against S100A4 effectively inhibits its expression.  
Expression of S100A4 was detected by (A) qRT-PCR, (B) Western blot 72 hours after 
specific knockdown of S100A4 at 2, 20, 200 nM in lung cancer cell lines. Knockdown 
with GL2 was also performed as the control.  
In (A), ratio of S100A4/B2M was calculated, and values were normalized by dividing 
by the ratio with no treatment (0 nM) to evaluate the efficiency of knockdown, and 
results of knockdown of GL2 and S100A4 are shown by white and grey bars, 
respectively.  
In (B), expression of ß-actin (ACTB) was monitored as the control, and the ratio of 
S100A4/ACTB was calculated by using densitometry, and values were normalized by 
dividing by the ratio with no treatment (0nM).  
62 
 
 
Figure 4. Effects of siRNA-mediated S100A4-knockdown to cell growth are shown. 
Knockdown experiments using siRNA against S100A4 at 2, 20, 200 nM were 
performed in HLC-1, 11-18, LK79, and SBC-3. Solid and dotted lines denote 
knockdown against S100A4 and GL2, respectively. Significant differences between 
cell proliferation were observed only in HLC-1 and LK79 (in A), while no such 
differences in the cell proliferation were observed in 11-18, SBC-3 (in B). *, **, and *** 
denote P < 0.05, P < 0.01, and P < 0.001 respectively.  
 
Figure 5. Effects of specific S100A4-knockdown to cell motility are shown.  
Results of scratch assay after siRNA-mediated knockdown of S100A4 at 200 nM in 
HLC-1, LK79 (in A, the S100A4-overexpressing cells), and 11-18, SBC-3 (in B, the 
S100A4-low expressing cells). Cells were seeded at 24 h after the siRNA transfection, 
and 24 h after the cell-seeding, the bottom of each well was scraped with the fine end 
of a micro-pipette tip. This time point was set as time 0. Distances were measured at 
various time points and are graphically demonstrated at the right; then, statistical 
analyses were done. 
 In (A), significant differences between cell migrations were observed in both HLC-1 
and LK79; * and ** denote P < 0.05 and P < 0.01 respectively. Representative pictures 
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are shown in the right columns. 
 In (B), No significant differences were observed. 
 In (C), Comparison of results of cell proliferation assay and scratch assay after 
siRNA-mediated knockdown of S100A4 at the same concentration (200nM). There 
were no statistically differences. GL2 was used as the control.  
 
Figure 6. S100A4 was successfully introduced and expressed in lung cancer cell 
lines. 
(A) After the co-transfection of pSUPER.retro.neo+GFP with pcDNA6-S100A4, Green 
fluorescein protein (GFP) emitting demonstrated the succeeding transfection of 
plasmids in these cells. Representative images are shown.  
(B) Results of RT-PCR after transfection of S100A4-expression construct, 
pcDNA6-S100A4. B2M was used as the internal control.  
(C) Western blot confirmed the exogenous expression of S100A4 after introduction of 
pcDNA6-S100A4 in these lung cancer cells. Myc-Tag antibody was used to monitor 
the induction of the pcDNA6/myc-His based plasmid pcDNA6-S100A4. MIA PaCa-2 
was used as the positive control, and ACTB was used as the internal control. 
 
Figure 7. Effects of forced expression of S100A4 on cell growth.  
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Cell proliferation assay demonstrated no differences after forced expression of 
S100A4 in both (A) 11-18 and SBC-3, the S100A4-low expressing cells and (B) 
HLC-1 and LK79, S100A4-overexpressing cells. Dotted and solid bars denote empty 
vector (Vector) and S100A4-expression vector (S100A4) transfected cells, 
respectively.  
 
Figure 8. Effects of forced expression of S100A4 on cell motility.  
Cells were seeded at 24 h after the transfection, and 24 h after the cell-seeding, the 
bottom of each well was scraped with the fine end of a micro-pipette tip. This time 
point was set as time 0. Distances were measured at various time points and are 
graphically demonstrated at the right; then, statistical analyses were done. 
Representative pictures are shown in the right columns.  
(A) Results of the scratch assay after forced expression of S100A4 in 11-18 and 
SBC-3. Significant differences between cell migrations were observed in both 11-18 
and SBC-3; *, **, and *** denote P < 0.05, P < 0.01, and P < 0.001 respectively. 
Representative pictures are shown in the right columns. 
(B) Results of the scratch assay after forced expression of S100A4 in HLC-1 and 
LK79. No significant differences were observed. Representative pictures are shown in 
the right columns. 
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Figure 9. Results of qRT-PCR of PRDM2 and VASH1 after siRNA-mediated 
knockdown of S100A4 (2, 20nM).  
B2M was used as the internal control. Expression levels were normalized using the 
mock-transfected (labeled as 0 nM) cells. PRDM2 was significantly upregulated at 72 
h after the transfection only in HLC-1 (P < 0.01), and no other differences were 
observed.  
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10. Tables 
 
 
 
Table 1. Nucleotide Sequences of the Primers and Probes, and PCR Conditions 
Gene    Primer sequence (5'→3') 
Annealing 
Temp. 
(
o
C) 
DMSO 
(%) 
Product 
size 
(bp) 
S100A4 
Forward 
primer 
AGAAGATCTCCACCATGGCGTGCCCTCTGGAG 
60 0 303 
 
Reverse 
primer 
TTACTCGAGTTTCTTCCTGGGCTGCTTAT 
 
Probe CAGGGACAACGAGGTGGACTT 
   
      
S100A4 
Forward 
primer 
TGCTTCTGAGATGTGGGCTTG 
60 0 142 
primer 
designed 
for bisulfite 
treatment  
Reverse 
primer 
CACAATTACCTTCTACCTTTC 
    
      
PRDM2 
Forward 
primer 
GAGCCAGATTTCACCTCTGC 
55 0 194 
 
Reverse 
primer 
GCTTCTAATCGCTCGTCTGG 
 
Probe CTGCAGAAG GT CCTAAAGAA 
   
      
VASH1 
Forward 
primer 
GGACCGGAAGAAGGATGTTT 
60 0 129 
 
Reverse 
primer 
TTAAGGTCTGGCATGGCTTTG 
  Probe GTGAAAGACGGCCCTCGGGT       
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